Cargando…
Downregulation of striatal Ca(V)1.3 inhibits the escalation of levodopa-induced dyskinesia in male and female parkinsonian rats of advanced age
In the past 25 years, the prevalence of Parkinson’s disease (PD) has nearly doubled. Age remains the primary risk factor for PD and as the global aging population increases this trend is predicted to continue. Even when treated with levodopa, the gold standard dopamine (DA) replacement therapy, indi...
Autores principales: | Caulfield, Margaret E., Werp, Molly J. Vander, Stancati, Jennifer A., Collier, Timothy J., Sortwell, Caryl E., Sandoval, Ivette M., Manfredsson, Fredric P., Steece-Collier, Kathy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324103/ https://www.ncbi.nlm.nih.gov/pubmed/37001610 http://dx.doi.org/10.1016/j.nbd.2023.106111 |
Ejemplares similares
-
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia
por: Steece‐Collier, Kathy, et al.
Publicado: (2019) -
Impact of age and vector construct on striatal and nigral transgene expression
por: Polinski, Nicole K, et al.
Publicado: (2016) -
Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia
por: Sellnow, Rhyomi C., et al.
Publicado: (2019) -
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron
graft efficacy and side-effect liability in rs6265 knock-in rats
por: Mercado, Natosha M., et al.
Publicado: (2020) -
Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates
por: Collier, Timothy J., et al.
Publicado: (2016)